Selvita S.A. (SLV) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue rose 19% year-over-year to PLN 91.2m, driven by both Drug Discovery and Drug Development segments.

• Net loss for the quarter was PLN 1.0m, an improvement from a PLN 2.1m loss in Q1 2024.

• Operating profit turned positive at PLN 0.3m, compared to a loss of PLN 2.1m in the prior year.

• Cash flow from operations was PLN 10.2m, down from PLN 18.5m in Q1 2024.

• No changes in group ownership; all subsidiaries remain fully consolidated.

Financial highlights

• Sales revenue: PLN 90.3m (Q1 2024: PLN 76.3m); total revenue including grants: PLN 91.2m.

• Operating expenses increased to PLN 91.0m (Q1 2024: PLN 79.4m), mainly due to higher employee costs.

• EBITDA not explicitly stated; operating profit at PLN 0.3m.

• Net loss: PLN 1.0m (Q1 2024: PLN 2.1m loss); EPS: PLN -0.05 (Q1 2024: PLN -0.12).

• Cash and equivalents at period end: PLN 15.5m (31/12/2024: PLN 22.5m).

Outlook and guidance

• No explicit forward guidance provided; management confirms going concern assumption for at least 12 months.